CompletedPhase 2NCT02161406
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dinesh Khanna, MD, MS
- Principal Investigator
- Dinesh Khanna, MD, MSUniversity of Michigan
- Intervention
- Abatacept(drug)
- Enrollment
- 88 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2018
Study locations (27)
- Arthritis Associates of Southern California, Los Angeles, California, United States
- University of California- Los Angeles, Los Angeles, California, United States
- Stanford University, Redwood City, California, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- Northwestern University, Chicago, Illinois, United States
- Harvard Mass General, Boston, Massachusetts, United States
- Boston University, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Rutgers University Clinical Research Center, New Brunswick, New Jersey, United States
- Steffens Scleroderma Center, Albany, New York, United States
- NorthWell Health, Great Neck, New York, United States
- Hospital for Special Surgery, New York, New York, United States
- Columbia University, New York, New York, United States
- +12 more locations on ClinicalTrials.gov
Collaborators
Bristol-Myers Squibb · National Institute of Allergy and Infectious Diseases (NIAID)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02161406 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University